Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carben DS is an oral combination supplement containing calcium carbonate (providing elemental calcium) and cholecalciferol (vitamin D3). Developed and marketed by Benham Pharmaceuticals in Bangladesh, it is formulated as a tablet containing 600 mg of elemental calcium and 400 IU of vitamin D3. Calcium is essential for bone mineralization, muscle contraction, nerve transmission, and blood coagulation, while vitamin D3 is a crucial pro-hormone that undergoes hydroxylation in the body to form calcitriol, which enhances intestinal calcium absorption. Carben DS is primarily indicated for the prevention and treatment of calcium and vitamin D deficiencies, and as an adjunct therapy in the management of bone disorders such as osteoporosis, osteomalacia, rickets, and latent tetany.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium carbonate + cholecalciferol (Benham Pharmaceuticals Ltd.).